|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang WQ, Fu FF, Li YX, Wang WB, Wang HH,
Jiang HP and Teng LS: Molecular biomarkers of colorectal cancer:
prognostic and predictive tools for clinical practice. J Zhejiang
Univ Sci B. 13:663–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
5
|
Lippman SM: The dilemma and promise of
cancer chemoprevention. Nat Clin Pract Oncol. 10:5232006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
7
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia L: Cancer complementary and
alternative medicine research at the US National Cancer Institute.
Chin J Integr Med. 18:325–332. 2012. View Article : Google Scholar
|
|
9
|
Carmady B and Smith CA: Use of Chinese
medicine by cancer patients: a review of surveys. Chin Med.
9:222011. View Article : Google Scholar
|
|
10
|
Liu J, Li X, Liu J, Ma L, Li X and Fønnebø
V: Traditional Chinese medicine in cancer care: a review of case
reports published in Chinese literature. Forsch Komplementmed.
18:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang GY, Li X, Li XL, Wang L, Li J, Song
X, Chen J, Guo Y, Sun X, Wang S, Zhang Z, Zhou X and Liu J:
Traditional Chinese medicine in cancer care: a review of case
series published in the chinese literature. Evid Based Complement
Alternat. 2012:1–8. 2012. View Article : Google Scholar
|
|
12
|
Newman DJ, Cragg GM and Snader KM: The
influence of natural products upon drug discovery. Nat Prod Rep.
17:215–234. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taixiang W, Munro AJ and Guanjian L:
Chinese medical herbs for chemotherapy side effects in colorectal
cancer patients. Cochrane Database of Systematic Reviews. (1):
CD004540 View Article : Google Scholar
|
|
14
|
Zhang M, Liu X, Li J, He L and Tripathy D:
Chinese medicinal herbs to treat the side-effects of chemotherapy
in breast cancer patients. Cochrane Database of Systematic Reviews.
(2): CD004921 View Article : Google Scholar
|
|
15
|
Chinese Pharmacopeia Commission.
Pharmacopoeia of the People's Republic of China Chinese. Medical
Science and Technology Press; Beijing: 263. 2010
|
|
16
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Ethyl acetate extraction
from a Chinese herbal formula, Jiedu Xiaozheng Yin, inhibits the
proliferation of hepatocellular carcinoma cells via induction of
G0/G1 phase arrest in vivo and in vitro. Int J Oncol. 42:202–210.
2013.PubMed/NCBI
|
|
17
|
Cao Z, Lin W, Huang Z, Chen X, Zhao J,
Zheng L, Ye H, Liu Z, Liao L and Du J: Jiedu Xiaozheng Yin, a
Chinese herbal formula, inhibits tumor angiogenesis via
downregulation of VEGF-A and VEGFR-2 expression in vivo and in
vitro. Oncol Rep. 29:1080–1086. 2013.PubMed/NCBI
|
|
18
|
Zheng LP, Chen YQ, Lin W, Zhuang QC, Chen
XZ, Xu W, Liu XX, Peng J and Sferra TJ: Spica Prunellae extract
promotes mitochondrion-dependent apoptosis in a human colon
carcinoma cell line. Afr J Phar Pharmacol. 5:327–335. 2011.
View Article : Google Scholar
|
|
19
|
Lin W, Zheng LP, Zhao JY, Zhuang QC, Hong
ZF, Xu W, Chen YQ, Sferra TJ and Peng J: Anti-angiogenic effect of
Spica Prunellae extract in vivo and in vitro. Afr J Phar Pharmacol.
24:2647–2654. 2011.
|
|
20
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nurse P: Ordering S phase and M phase in
the cell cycle. Cell. 79:547–550. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Robles AI, Martinez LA, Liu F,
Gimenez-Conti IB and Conti CJ: Expression of G1 cyclins,
cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in
androgen-induced prostate proliferation in castrated rats. Cell
Growth Differ. 7:1571–1578. 1996.PubMed/NCBI
|
|
24
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
25
|
Zafonte BT, Hulit J, Amanatullah DF,
Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP and
Pestell RG: Cell-cycle dysregulation in breast cancer: breast
cancer therapies targeting the cell cycle. Front Biosci.
5:D938–D961. 2000. View
Article : Google Scholar : PubMed/NCBI
|
